Before We Start
Why "trade-off" is the right way to think about this medication class
There is no antipsychotic medication that avoids side effects entirely — the real clinical decision is which side effect profile is the better fit for a given patient. Typical and atypical antipsychotics represent genuinely different trade-offs, not simply an "older, worse" option versus a "newer, better" one. Understanding both profiles clearly is what allows for informed decision-making and patient counseling.
💡 The Core Trade-off in One Line
1st generation (typical) antipsychotics trade a higher risk of movement-related side effects (EPS) for effectiveness against positive symptoms. 2nd generation (atypical) antipsychotics trade a lower EPS risk for a higher risk of metabolic side effects.
Mnemonic
The two classes, side by side
T — Typical (1st Generation)
Examples: haloperidol, chlorpromazine (Thorazine)
High EPS risk (dystonia, akathisia, pseudoparkinsonism — see the dedicated ADAPT lesson) and high tardive dyskinesia risk with longer-term use. Effective specifically for positive symptoms (hallucinations, delusions, disorganized thinking).
A — Atypical (2nd Generation)
Examples: olanzapine, risperidone, quetiapine
Lower EPS risk compared to typical antipsychotics, but a meaningful risk of metabolic syndrome — weight gain, elevated blood glucose (risk of new-onset diabetes), and dyslipidemia (abnormal cholesterol/lipid levels). These metabolic effects require their own dedicated, ongoing monitoring throughout treatment, not just an initial assessment.
C — Clozapine
Most effective overall, but reserved as a last resort
Widely regarded as the most effective antipsychotic available, but reserved specifically for treatment-resistant cases due to the risk of agranulocytosis, requiring mandatory weekly CBC monitoring (see the ADAPT lesson for how this fits into the broader antipsychotic side-effect timeline).
💊 A useful way to remember the trade-off: typical antipsychotics primarily risk the nervous system (movement disorders); atypical antipsychotics primarily risk the metabolic system (weight, blood sugar, lipids) — two very different systems, two very different monitoring priorities.
Universal Monitoring
What applies across both classes
QTc Prolongation
A shared cardiac risk across antipsychotics generally
Regardless of which class or specific medication, QTc prolongation (a change in the heart's electrical cycle that can predispose to dangerous arrhythmias) is a monitoring concern across antipsychotics as a category — this isn't unique to just one class, and baseline and periodic ECG monitoring may be appropriate depending on the specific medication and patient risk factors.
🏥 Clinical Scenario — Choosing a Monitoring Plan Based on Medication Class
A patient is newly started on olanzapine (an atypical antipsychotic) for schizophrenia. A student nurse asks what specific monitoring should be prioritized.
Apply the Class-Specific Trade-off
Since olanzapine is an atypical (2nd generation) antipsychotic, the primary monitoring priority shifts toward metabolic parameters — weight, blood glucose, and lipid panel — rather than the EPS-focused monitoring that would be more central with a typical antipsychotic like haloperidol. This doesn't mean EPS monitoring is skipped entirely (atypicals still carry some EPS risk), but the balance of concern shifts based on the specific medication class.
Establish Baseline and Ongoing Monitoring
The nurse ensures baseline weight, glucose, and lipid values are documented before or shortly after starting the medication, with a plan for periodic reassessment throughout treatment. A single baseline check isn't sufficient — metabolic side effects can develop and progress over the course of treatment, requiring ongoing monitoring rather than a one-time assessment.
Educate the Patient
The nurse also provides patient education about the metabolic risk specifically, including the importance of reporting significant weight changes or symptoms suggestive of elevated blood glucose. Patient awareness supports earlier detection of metabolic changes between formal monitoring checkpoints.
📌 NCLEX Application
Antipsychotic class questions test matching monitoring priorities to the specific medication class:
Class-based monitoring: "A patient is started on risperidone. What monitoring should the nurse prioritize?" → Metabolic parameters — weight, blood glucose, and lipid panel — given risperidone's atypical (2nd generation) classification.
Trade-off understanding: "Why might a provider choose a typical antipsychotic despite its higher EPS risk?" → Typical antipsychotics can be particularly effective for positive symptoms, and the trade-off decision depends on the specific patient's symptom profile and risk factors.
Clozapine positioning: "Why is clozapine not typically used as a first-line antipsychotic despite being highly effective?" → Its agranulocytosis risk requires mandatory weekly CBC monitoring, making it a reserved, later-line option.
⚠️ The Trap — Assuming Atypical Antipsychotics Are Simply "Safer" Overall
Because atypical antipsychotics carry a lower EPS risk, it's tempting to think of them as a strictly safer or better option compared to typical antipsychotics. But their metabolic risk profile is a genuine, sometimes serious trade-off — weight gain, diabetes risk, and dyslipidemia carry their own significant long-term health consequences, not a lesser concern than EPS.
The safeguard: Think of the choice between typical and atypical antipsychotics as a genuine trade-off between two different risk categories, not a simple hierarchy from worse to better.
✓ Quick Self-Test
Answer before checking:
1. What is the primary side-effect trade-off between typical and atypical antipsychotics?
2. Name two examples each of typical and atypical antipsychotics.
3. Why is clozapine reserved as a later-line option despite being highly effective?
4. What cardiac monitoring concern applies across antipsychotics generally, regardless of class?
Answers:
1. Typical antipsychotics carry higher EPS risk; atypical antipsychotics carry higher metabolic risk (weight gain, glucose, lipids).
2. Typical: haloperidol, chlorpromazine. Atypical: olanzapine, risperidone (quetiapine also correct).
3. Due to its risk of agranulocytosis, requiring mandatory weekly CBC monitoring.
4. QTc prolongation.
Next Lesson
Benzodiazepines, SSRIs, and Buspirone
→